-
21.发明申请HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS 有权羟基和甲氧基吡咯烷酮作为AKT蛋白激酶抑制剂公开(公告)号：US20160152606A9
公开(公告)日：2016-06-02
申请号：US14458062
申请日：2014-08-12
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： Ian S. Mitchell , James F. Blake , Rui Xu , Nicholas C. Kallan , Dengming Xiao , Keith Lee Spencer , Josef R. Bencsik , Eli M. Wallace , Stephen T. Schlachter , Anna L. Leivers , Jun Liang , Brian Safina , Birong Zhang , Christine Chabot , Steven Do
IPC: C07D413/12 , C07D401/12 , C07D409/14 , C07D407/12 , C07D409/12 , C07D239/70 , C07D403/12
CPC classification number: A61K31/517 , C07D239/70 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12
Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Abstract translation: 本发明提供了包含分解的对映异构体，分解的非对映异构体，溶剂合物和其药学上可接受的盐的化合物，其包含式I：还提供了使用本发明化合物作为AKT蛋白激酶抑制剂和用于治疗过度增殖性疾病 癌症。
-
公开(公告)号：US20140315887A1
公开(公告)日：2014-10-23
申请号：US14321468
申请日：2014-07-01
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： Josef R. Bencsik , James F. Blake , Nicholas C. Kallan , Ian S. Mitchell , Keith L. Spencer , Dengming Xiao , Rui Xu , Christine Chabot , Jun Liang , Brian S. Safina
IPC: C07D409/12 , C07D403/12 , C07D239/70
CPC classification number: C07D239/70 , A61K31/506 , C07D401/12 , C07D403/12 , C07D409/12
Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
-
23.发明申请公开(公告)号：US20150191479A1
公开(公告)日：2015-07-09
申请号：US14516443
申请日：2014-10-16
Applicant: Array BioPharma Inc.
Inventor： Ian S. Mitchell , James F. Blake , Rui Xu , Nicholas C. Kallan , Dengming Xiao , Keith Lee Spencer , Josef R. Bencsik
IPC: C07D491/048 , A61K45/06 , A61K31/519
CPC classification number: C07D491/048 , A61K31/519 , A61K45/06 , A61K2300/00
Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Abstract translation: 本发明提供了包括分解对映异构体，非对映异构体，溶剂合物和其药学上可接受的盐的化合物，其包含式：还提供使用本发明化合物作为AKT蛋白激酶抑制剂和治疗过度增殖性疾病如癌症的方法。
-
24.发明申请公开(公告)号：US20130072500A1
公开(公告)日：2013-03-21
申请号：US13676963
申请日：2012-11-14
Applicant: Array BioPharma Inc.
Inventor： Anna Banka , Josef R. Bencsik , James F. Blake , Kin Chiu Fong , Martin F. Hentemann , Ian S. Mitchell , Douglas McCord Sammond , Tony P. Tang , Eli M. Wallace , Rui Xu
IPC: C07D471/10 , C07D487/10
CPC classification number: C07D471/10 , C07D487/10
Abstract: The present invention provides compounds of Formula I including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.
Abstract translation: 本发明提供式I化合物，其包括互变异构体，拆分的对映异构体，拆分的非对映体，溶剂合物，代谢物，盐和药学上可接受的前药。 还提供了使用本发明化合物作为Akt蛋白激酶抑制剂和治疗Akt介导的疾病例如过度增殖性疾病如癌症的方法。
-
25.发明申请N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS 有权N-BICYCLIC ARYL，N'-PYRAZOLYL UREA，THIOUREA，GUANIDINE AND CYANOGUANIDINE COMPOUNDS as TRKA KINASE INHIBITORS公开(公告)号：US20160280681A1
公开(公告)日：2016-09-29
申请号：US14442584
申请日：2013-11-12
Applicant: ARRAY BIOPHARMA INC.
Inventor： Shelley Allen , James F. Blake , Barbara J. Brandhuber , Yutong Jiang , Gabrielle R. Kolakowski , Rui Xu , Shannon L. Winski
IPC: C07D401/14 , C07D231/56 , C07D231/52 , C07D403/04 , C07D401/12 , C07D401/04 , C07D231/40
CPC classification number: C07D401/14 , C07D231/40 , C07D231/44 , C07D231/52 , C07D231/56 , C07D401/04 , C07D401/12 , C07D403/04
Abstract: Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
-
Patent Agency Ranking
公开(公告)号：US09346805B2
公开(公告)日：2016-05-24
申请号：US13676963
申请日：2012-11-14
Applicant: Array BioPharma Inc.
Inventor： Anna Banka , Josef R. Bencsik , James F. Blake , Kin Chiu Fong , Martin F. Hentemann , Ian S. Mitchell , Douglas McCord Sammond , Tony P. Tang , Eli M. Wallace , Rui Xu , James Graham
IPC: C07D471/10 , C07D487/10
CPC classification number: C07D471/10 , C07D487/10
Abstract: The present invention provides compounds of Formula I including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.
Abstract translation: 本发明提供式I化合物，其包括互变异构体，拆分的对映异构体，拆分的非对映体，溶剂合物，代谢物，盐和药学上可接受的前药。 还提供了使用本发明化合物作为Akt蛋白激酶抑制剂和治疗Akt介导的疾病例如过度增殖性疾病如癌症的方法。
-
公开(公告)号：US20140148436A1
公开(公告)日：2014-05-29
申请号：US14170272
申请日：2014-01-31
Applicant: Array BioPharma, Inc.
Inventor： Ian S. Mitchell , Keith L. Spencer , Peter Stengel , Yongxin Han , Nicolas C. Kallan , Mark Munson , Guy P.A. Vigers , James Blake , Anthony Piscopio , John Josey , Scott Miller , Dengming Xiao , Rui Xu , Chang Rao , Bing Wang , April L. Bernacki
IPC: C07D239/94 , C07D403/12 , C07D495/04 , C07D491/048 , C07D231/56 , C07D401/12 , C07D409/04 , C07D401/04 , C07D409/12 , C07D487/04
CPC classification number: C07D239/94 , B41M3/008 , B44F1/10 , C07D231/56 , C07D237/28 , C07D239/42 , C07D239/47 , C07D239/48 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D409/04 , C07D409/12 , C07D471/04 , C07D487/04 , C07D491/048 , C07D495/04 , G09F13/16 , Y10T428/24802 , Y10T428/24851 , Y10T428/25 , Y10T428/31507 , Y10T428/31551 , Y10T428/31786 , Y10T428/31855
Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Abstract translation: 本发明提供包括分解对映异构体，非对映异构体，溶剂化物和药学上可接受的盐的化合物，其包含式为：A-L-CR，其中CR为环状核心基团，L为连接基团，A如本文所定义。 还提供了使用本发明化合物作为AKT蛋白激酶抑制剂和治疗过度增殖性疾病如癌症的方法。
-
公开(公告)号：US20130065908A1
公开(公告)日：2013-03-14
申请号：US13672546
申请日：2012-11-08
Applicant: Array BioPharma Inc.
Inventor： Ian S. Mitchell , James F. Blake , Rui Xu , Nicholas C. Kallan , Dengming Xiao , Keith Lee Spencer , Josef R. Bencsik
IPC: A61K31/519 , A61P29/00 , A61P17/00 , A61P9/00 , A61P25/28 , A61P15/00 , C07D491/048 , A61P35/00
CPC classification number: C07D491/048 , A61K31/519 , A61K45/06 , A61K2300/00
Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
-
29.发明授权N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors 有权N-双环芳基，N'-吡唑基脲，硫脲，胍氰腈化合物作为TrkA激酶抑制剂公开(公告)号：US09546156B2
公开(公告)日：2017-01-17
申请号：US14442584
申请日：2013-11-12
Applicant: Array BioPharma Inc.
Inventor： Shelley Allen , James F. Blake , Barbara J. Brandhuber , Yutong Jiang , Gabrielle R. Kolakowski , Rui Xu , Shannon L. Winski
IPC: C07D231/40 , C07D231/52 , C07D231/56 , C07D401/04 , C07D401/12 , C07D403/04 , C07D401/14
CPC classification number: C07D401/14 , C07D231/40 , C07D231/44 , C07D231/52 , C07D231/56 , C07D401/04 , C07D401/12 , C07D403/04
Abstract: Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
Abstract translation: 式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，溶剂合物或前药，其中环A，环C和X如本文所定义，是TrkA激酶的抑制剂，并且可用于治疗可以 用TrkA激酶抑制剂治疗，如疼痛，癌症，炎症/炎性疾病，神经变性疾病，某些传染病，干燥综合征，子宫内膜异位症，糖尿病性周围神经病变，前列腺炎或骨盆疼痛综合征。
-
公开(公告)号：US20160152576A9
公开(公告)日：2016-06-02
申请号：US14170272
申请日：2014-01-31
Applicant: Array BioPharma, Inc.
Inventor： Ian S. Mitchell , Keith L. Spencer , Peter Stengel , Yongxin Han , Nicolas C. Kallan , Mark Munson , Guy P.A. Vigers , James Blake , Anthony Piscopio , John Josey , Scott Miller , Dengming Xiao , Rui Xu , Chang Rao , Bing Wang , April L. Bernacki
IPC: C07D239/94 , C07D403/12 , C07D495/04 , C07D491/048 , C07D231/56 , C07D401/12 , C07D409/04 , C07D401/04 , C07D409/12 , C07D487/04
CPC classification number: C07D239/94 , B41M3/008 , B44F1/10 , C07D231/56 , C07D237/28 , C07D239/42 , C07D239/47 , C07D239/48 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/12 , C07D409/04 , C07D409/12 , C07D471/04 , C07D487/04 , C07D491/048 , C07D495/04 , G09F13/16 , Y10T428/24802 , Y10T428/24851 , Y10T428/25 , Y10T428/31507 , Y10T428/31551 , Y10T428/31786 , Y10T428/31855
Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Abstract translation: 本发明提供包括分解对映异构体，非对映异构体，溶剂化物和药学上可接受的盐的化合物，其包含式为：A-L-CR，其中CR为环状核心基团，L为连接基团，A如本文所定义。 还提供了使用本发明化合物作为AKT蛋白激酶抑制剂和治疗过度增殖性疾病如癌症的方法。
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.039 seconds)
